SANTA FE, NEW MEXICO: Health advocates are renewing calls for New Mexico to expand Medicaid coverage for prescription weight loss medications, arguing that access to obesity treatment should not depend on a person’s income.
The proposal comes as the state faces rising prescription drug spending, persistent obesity-related health disparities and pressure to control Medicaid costs.
Officials must weigh the potential benefits of broader treatment against the financial impact on the public healthcare program.
Advocates Seek Wider Drug Access
Health advocates are urging New Mexico to make prescription medications approved for chronic weight management more accessible to Medicaid beneficiaries.
They argue that obesity is a complex medical condition influenced by genetics, income, food access, working conditions and other social factors.
The campaign includes organizations such as the National Hispanic Health Foundation, National Hispanic Council on Aging, League of United Latin American Citizens, American Diabetes Association and MANA, a national Latina advocacy organization.
The coalition’s position is that low-income patients should have access to medically appropriate obesity treatment rather than face financial barriers to prescribed medications.
As reported by The Santa Fe New Mexican, advocates have renewed their push for wider coverage as state officials consider healthcare priorities and the cost of prescription treatments.
The debate also challenges the idea that obesity results only from individual lifestyle choices.
People working long hours or living in communities with limited access to affordable nutritious food may face additional barriers to managing their weight.
Advocates argue that access to effective medical treatment should form part of a broader approach to reducing these inequalities.
What Medicaid Covers Today
New Mexico Medicaid covers certain medications for weight management, but eligibility rules and restrictions limit access for some patients.
Under the reported fee-for-service criteria, beneficiaries may need a body mass index (BMI) above 40, or above 35 with additional risk factors such as diabetes or high blood pressure.
Treatment may also require documentation of a trial of calorie restriction and increased physical activity.
These requirements can make it difficult for patients who do not meet the program’s thresholds to obtain coverage, even when a healthcare professional considers medication appropriate.
The coverage debate particularly concerns glucagon-like peptide-1 receptor agonists, known as GLP-1 medications.
These drugs act on pathways involved in appetite regulation and blood sugar control.
Depending on the specific medication, they may be approved for Type 2 diabetes, chronic weight management or other indications.
Medicaid coverage depends on the drug’s approved use and applicable federal and state rules.
Coverage for diabetes treatment does not automatically mean that the same medication is covered when prescribed specifically for obesity.
Expanding the benefit would require the state to determine which medications qualify, which patients meet the clinical criteria and what safeguards should apply to prescribing and monitoring.
Obesity Rates Across New Mexico
Obesity remains a significant public health concern in New Mexico.
State health data cited in the reporting shows that adult obesity prevalence increased from 26% in 2013 to 35% in 2023.
In adults, a BMI of 30 or higher generally falls within the obesity category.
BMI is a screening measure based on height and weight, not a complete assessment of body composition or individual health.
Obesity is associated with an increased risk of Type 2 diabetes, cardiovascular disease, high blood pressure and other chronic conditions.
Effective treatment may help some patients improve their health and manage these risks.
The burden is not distributed equally across the state.
Reported disparities affect Native American and Hispanic residents, people living in rural communities and households earning less than $25,000 annually.
These differences have strengthened calls for more affordable treatment options.
People with limited incomes may struggle to pay for expensive prescription medications, particularly when insurance does not cover their use for weight management.
Advocates say broader coverage could help reduce these barriers, although medication access alone cannot address all the social and economic factors associated with obesity.
Prescription Costs Challenge Expansion
The cost of prescription drugs remains a major concern for New Mexico’s Medicaid program.
A fiscal impact report for Senate Bill 193, introduced in 2025, estimated that a proposed requirement for insurance coverage of weight management medications could add between $9.5 million and $84.2 million in Medicaid costs, depending on utilization and other assumptions.
The bill did not receive a hearing. Its projected costs therefore represent estimates for a proposed policy, not spending under an approved expansion.
More recent figures underline the wider pressure on the state’s prescription budget.
According to a September 2026 report by Searchlight New Mexico, the state’s Medicaid program spent $38.7 million on Ozempic in 2025.
Spending on the drug had risen by more than 34% from 2024 and more than doubled compared with 2023.
Ozempic is approved to treat Type 2 diabetes, and its reported Medicaid expenditure should not be interpreted as the cost of providing obesity-specific coverage.
The figures nevertheless illustrate the growing financial significance of medications in the GLP-1 class.
Medication prices, the number of eligible patients, treatment duration, negotiated prices and prescribing patterns would all influence the cost of an expanded benefit.
The state must also consider the effect of federal healthcare funding changes.
New Mexico’s Health Care Authority has projected an $8.5 billion reduction in federal funding for provider payments between 2028 and 2037 as a result of the 2025 federal budget reconciliation law.
These pressures make it important to assess the affordability of broader medication coverage alongside other Medicaid services.
Potential Savings Remain Uncertain
Supporters argue that expanding obesity treatment could help prevent or delay some costly chronic diseases.
Obesity is associated with conditions that can require long-term medication, specialist care and hospital treatment.
For some patients, appropriate weight management treatment can improve health outcomes and reduce certain risk factors.
However, the potential savings from wider medication coverage remain uncertain.
They would depend on the effectiveness of treatment, the duration of use, medication prices and the extent to which improved health reduces other medical expenses.
New Mexico lawmakers have also questioned whether proposed coverage expansions would produce enough savings to offset their costs.
Representative Liz Thomson of Albuquerque has highlighted the difficulty of comparing the projected cost of legislation with the healthcare spending it might eventually prevent.
A reliable assessment would require evidence on both expenditure and patient outcomes over time.
The financial case for expansion therefore depends on more than the cost of the medication itself.
It also requires a clear understanding of long-term treatment needs and measurable health benefits.
Risks of Unsafe Weight Loss Drugs
Limited access to affordable treatment can create pressure for some patients to seek cheaper alternatives, including compounded medications or products sold through unverified online sources.
Compounded drugs are prepared by pharmacies or other authorized facilities under specific circumstances.
They are not the same as FDA-approved, commercially manufactured medicines and do not undergo the same premarket review for safety, effectiveness and quality.
The U.S. Food and Drug Administration has warned about dosing errors involving compounded GLP-1 medications. Incorrect doses can cause severe nausea, vomiting and dehydration, while other serious complications may require medical attention.
Potential adverse effects associated with GLP-1 medicines can also include pancreatitis and gallbladder problems, depending on the drug and the patient.
New Mexico’s Department of Justice issued a consumer warning in 2025 concerning risks associated with weight loss products and unsafe medication use.
Such warnings highlight the importance of obtaining prescription medicines through legitimate healthcare channels and following a qualified healthcare professional’s instructions.
Advocates argue that improved access to approved treatments could reduce the pressure on patients to seek unverified alternatives.
However, the extent to which expanded Medicaid coverage would change this behaviour has not been established.
State Officials Weigh Next Steps
The New Mexico Health Care Authority has continued evaluating options for obesity medication coverage as drug choices, dosages and pricing arrangements evolve.
Keenan Ryan, the agency’s acting chief medical officer and director of pharmacy, has described the issue as one that requires continued assessment.
Any expansion would require the state to establish eligibility requirements, clinical safeguards, budget provisions and administrative procedures.
Officials would also need to determine how coverage could be sustained alongside other healthcare priorities.
The policy debate is taking place amid wider changes to Medicaid funding and prescription spending.
These factors could influence both the timing and the design of any future expansion.
As of the reporting covered here, broader coverage should not be treated as an approved policy.
Beneficiaries must continue to rely on the rules applicable to their specific Medicaid coverage and prescribed medication.
Access Versus Affordability
New Mexico’s debate over weight loss medication coverage reflects a wider challenge for public healthcare programs: providing access to effective treatment while managing rising pharmaceutical costs.
Advocates argue that expanding coverage could reduce financial barriers and help address obesity-related health disparities.
State officials must determine whether the expected health benefits justify the additional spending and how the program can remain financially sustainable.
The eventual decision will depend on policy choices, available funding, clinical evidence and the cost of treatment.
Until the state approves a defined expansion, broader Medicaid coverage for obesity medications remains a proposal rather than a guaranteed benefit.
Stay tuned with us for more health related topics.
Follow us on LinkedIn and Instagram for more.
